

CONFERENCE COMMITTEE REPORT

SB 43

2026 Regular Session

McMath

May 25, 2026

To the Honorable President and Members of the Senate and to the Honorable Speaker and Members of the House of Representatives.

Ladies and Gentlemen:

We, the conferees appointed to confer over the disagreement between the two houses concerning Senate Bill No. 43 by Senator McMath, recommend the following concerning the Reengrossed bill:

- 1. That the House Committee Amendments proposed by the House Committee on Health and Welfare and adopted by the House of Representatives on May 5, 2026, be adopted.
- 2. That the House Floor Amendments proposed by Representative Riser and adopted by the House of Representatives on May 7, 2026, be adopted.
- 3. That the following amendment be adopted:

AMENDMENT NO. 1

In House Floor Amendment No. 10 by Representative Riser, on page 1, line 26, after "delete" insert "**of ibogaine as a medication**" and insert"

Respectfully submitted,

Senators:

Representatives:

Senator Patrick McMath

Representative Neil Riser

Senator W. Jay Luneau

Representative Dustin Miller

Senator Robert "Bob" Owen

Representative Peter Egan

The legislative instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Senate Legislative Services. The keyword, summary, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

CONFERENCE COMMITTEE REPORT DIGEST

SB 43

2026 Regular Session

McMath

Keyword and summary of the bill as proposed by the Conference Committee

HEALTH SERVICES: Provides relative to psychedelic-assisted therapy. (8/1/26)

Report adopts House amendments to:

1. Add to definition of "psychedelic medication".
2. Add identification of a state point of contact to coordinate with federal agencies and other states regarding psychedelic assisted therapy and related drug development.
3. Add encouragement and use of opioid settlement funds and other related monies to support trial and trial-enabling studies.
4. Make further clarification regarding attributable revenue from newly developed intellectual property as a result of the clinical trial activity.

Report amends the bill to:

1. Make a technical correction.

Digest of the bill as proposed by the Conference Committee

Proposed law establishes the Psychedelic-Assisted Therapy Initiative within the La. Dept. of Health, office of behavioral health.

Proposed law establishes the following purposes of the initiative:

- (1) To identify academic health centers that are conducting clinical studies and clinical trial-enabling studies for the use of psychedelic-assisted therapy for the treatment of opioid use disorders, co-occurring substance use disorders, and treatment-resistant neurological or mental health conditions.
- (2) To utilize the human service districts and authorities to identify eligible participants.
- (3) To provide information to allow parishes utilizing opioid settlement funds to enroll eligible patients residing in the parish to participate in the studies or to support clinical trial-enabling studies.
- (4) To designate a state point of contact to coordinate with federal agencies and other states with regard to psychedelic assisted therapy and related drug development.

Proposed law authorizes the department to seek and receive federal funds, gifts, grants, and donations for the program in addition to utilizing opioid settlement funds.

Proposed law requires participating academic health centers to submit an annual progress report to the department and requires the department to submit a compiled report to the legislature by March first of each year.

Proposed law requires the participating academic health centers to coordinate with other states that are conducting clinical trials for the use of psychedelic-assisted therapy to the extent feasible.

Proposed law authorizes academic health centers to enter into agreements with drug developers to establish a consortium for purposes of conducting drug development clinical trials with ibogaine and psychedelic medication treatments and provides for the process to establish a consortium.

Proposed law provides for the distribution of any revenue attributable to newly developed intellectual property rights and other commercial rights arising from a drug development clinical trial, including that not less than two and one half percent of net sales running royalty to the state.

Effective August 1, 2026.

(Adds R.S. 28:211 and 212)